Efficacy News and Research

RSS

AI could enhance prediction of treatment response among patients with non-small cell lung cancer

Artificial intelligence deep learning algorithms may predict response to systemic treatment for non-small cell lung cancer.

23 Mar 2020

Coronavirus & the 2nd generation NObreath update

COVID-19, more commonly referred to as Coronavirus, has become an increasing concern, especially in the world of medical devices.

From Bedfont® Scientific Ltd 23 Mar 2020

Coronavirus & Bedfont products update

COVID-19, more commonly referred to as Coronavirus, has become an increasing concern, especially in the world of medical devices.

From Bedfont® Scientific Ltd 23 Mar 2020

University of Queensland race to accelerate COVID-19 vaccine research

A funding injection of up to $17 million for vital University of Queensland research could help cut the timeline for an effective vaccine for COVID-19 by six months.

22 Mar 2020

Preclinical study characterizes the binding affinity and selectivity of a selective FLT3 inhibitor

Oncotarget Volume 11, Issue 11 reported that in this preclinical study, we characterized the binding affinity and selectivity of quizartinib, a small-molecule inhibitor of FLT3, and AC886, the active metabolite of quizartinib, compared with those of other FLT3 inhibitors.

21 Mar 2020

AI may help predict tumor sensitivity to systemic cancer therapies

Using standard-of-care computed tomography scans in patients with advanced non-small cell lung cancer, researchers utilized artificial intelligence to train algorithms to predict tumor sensitivity to three systemic cancer therapies.

20 Mar 2020

Researchers highlight urgent need for public health leadership during COVID-19 pandemic

For decades, public health officials have directed the containment of emerging pandemics - perhaps most notably - the worldwide eradication of smallpox starting in the early to mid-1960s.

19 Mar 2020

Lopinavir and ritonavir drug combo tested in severe COVID-19

Researchers from China and the United Kingdom have collaborated to conduct a clinical trial looking at the efficacy of a combination of two anti-HIV drugs lopinavir and ritonavir to combat severe cases of COVID-19. Their study titled, “A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe COVID-19,” was published in the latest issue of the New England Journal of Medicine (NEJM).

19 Mar 2020

Targeting PI3Kβ alone and with combination therapy in PTEN-deficient tumors

The cover for issue 11 of Oncotarget features Figure 6, "Effects of AZD8186 in combination with anti-PD1 on syngeneic models," by Owusu-Brackett, et al.

18 Mar 2020

Researchers identify new way to treat Danon disease using gene therapy

Danon disease is a very rare, life-threatening condition where the fundamental biological process of removing and recycling proteins does not work.

18 Mar 2020

Why is the tobacco industry supporting wider access to medical cannabis?

A new study published in the BMJ reveals disturbing connections between organizations and groups that are lobbying for broader access to medical cannabis and those who are fighting for the legalization of recreational cannabis. This raises questions as to the reasons behind the industry’s support for measures that will make it easier for patients to gain access to medical cannabis – is it because of the knowledge that by so doing, they will also be able to market the drug for recreational use in the UK?

18 Mar 2020

Engineered botox more effective

A new study reports on an engineered botulinum neurotoxin (botox) that is more effective as well as safer to use in various medical procedures. The study was published in March 2020 in the open-access journal PLOS Biology.

17 Mar 2020

AI-powered, smart insole turns any shoe into portable gait-analysis laboratory

Researchers at Stevens Institute of Technology have developed an AI-powered, smart insole that instantly turns any shoe into a portable gait-analysis laboratory.

17 Mar 2020

Trial of cancer drug OxaliTex promises lower toxicity and more robust action

Preclinical trials indicate that a drug candidate called OxaliTex can stop the growth of cancer cells completely. OxaliTex appears to be more potent than many other common chemotherapy drugs, with less toxicity and less rapidly counteracted by mechanisms of drug resistance. The study was reported in the journal Proceedings of the National Academy of Sciences in March 2020.

16 Mar 2020